Drugs / MEDI8852
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02350751 | Jan → Jun 2015 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02603952 | Dec 2015 → Dec 2016 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03903718 | Apr → Oct 2020 | influenza | MedImmune LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03028909 | Jul 2017 → Jul 2019 | — | MedImmune LLC | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-03-07 | AstraZeneca | Regulatory MedImmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A astrazeneca.com ↗
AstraZeneca today announced that its global biologics research and development arm, MedImmune, has received Fast Track designation from the US Food and Drug Administration (FDA) for its investigational human monoclonal antibody (mAb), MEDI8852, for the treatment of patients hospitalised with Type A strain influenza. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-03-07 | AstraZeneca | MedImmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza A astrazeneca.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI8852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02603952 ↗ |
| Known as | Pan-influenza a mab medi8852 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298034 ↗ |
| Modality | Monoclonal antibody | “MEDI8852 is an IgG1 kappa monoclonal antibody” PMID 28844541 ↗ Aug 2017 |
| Route | Intravenous | “Investigational product will be delivered intravenously (IV).” NCT02350751 ↗ |